Boys aged 8 to 9 with Duchenne muscular dystrophy (DMD) who received the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) showed significant improvements in motor function compared to untreated patients with the disease, suggesting the therapy could slow DMD’s progression during a stage when physical decline is typically expected, according to findings from the phase 3 EMBARK clinical trial .

According to the Muscular Dystrophy Association, DMD is the most common type of muscular dystrophy, affecting approximately 1 in every 5,000 live male births.

DMD is a serious genetic disorder that causes progressive muscle weakness and deterioration, especially in the skeletal muscles that control movement.

An estimated 20,000 children worldwide are diagnosed with DMD each year.

This c

See Full Page